logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9944618 B1

PDFFull Text
Date of Patent:
Apr. 17, 2018

Filed:

Mar. 10, 2014

Inhibiting neurotransmitter reuptake

Applicants:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Virginia Tech Intellectual Properties, Inc., Blacksburg, VA (US);

Inventors:

Elliott Richelson, Ponte Vedra Beach, FL (US);

Abdul H. Fauq, Jacksonville, FL (US);

Paul Carlier, Blacksburg, VA (US);

Christopher J. Monceaux, Christiansburg, VA (US);

Assignees:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Virginia Tech Intellectual Properties, Inc., Blacksburg, VA (US);

Attorney:

Fish & Richardson P.C.

Primary Examiner:

Clinton Brooks

Int. Cl.
CPC ...
C07D 333/28 (2006.01); C07C 259/06 (2006.01); C07C 211/30 (2006.01); A61K 31/138 (2006.01); C07C 215/28 (2006.01); C07C 215/68 (2006.01); C07C 217/48 (2006.01); C07C 217/62 (2006.01); C07C 217/64 (2006.01); C07C 233/43 (2006.01); C07C 235/06 (2006.01); C07C 235/08 (2006.01); C07D 317/58 (2006.01); C07D 319/18 (2006.01); C07D 333/20 (2006.01); C07D 261/08 (2006.01); C07D 265/06 (2006.01); C07D 267/10 (2006.01); C07D 207/12 (2006.01); C07D 271/06 (2006.01); C07D 295/135 (2006.01); C07D 295/185 (2006.01); C07D 213/30 (2006.01); C07D 213/61 (2006.01); C07D 213/64 (2006.01); C07D 213/65 (2006.01); C07C 215/30 (2006.01); C07C 235/14 (2006.01); C07C 323/32 (2006.01); C07D 205/04 (2006.01); C07D 213/38 (2006.01); C07D 215/06 (2006.01); C07D 295/192 (2006.01);
U.S. Cl.
CPC ...
C07D 333/28 (2013.01); A61K 31/138 (2013.01); C07C 211/30 (2013.01); C07C 215/28 (2013.01); C07C 215/30 (2013.01); C07C 215/68 (2013.01); C07C 217/48 (2013.01); C07C 217/62 (2013.01); C07C 217/64 (2013.01); C07C 233/43 (2013.01); C07C 235/06 (2013.01); C07C 235/08 (2013.01); C07C 235/14 (2013.01); C07C 259/06 (2013.01); C07C 323/32 (2013.01); C07D 205/04 (2013.01); C07D 207/12 (2013.01); C07D 213/30 (2013.01); C07D 213/38 (2013.01); C07D 213/61 (2013.01); C07D 213/64 (2013.01); C07D 213/65 (2013.01); C07D 215/06 (2013.01); C07D 261/08 (2013.01); C07D 265/06 (2013.01); C07D 267/10 (2013.01); C07D 271/06 (2013.01); C07D 295/135 (2013.01); C07D 295/185 (2013.01); C07D 295/192 (2013.01); C07D 317/58 (2013.01); C07D 319/18 (2013.01); C07D 333/20 (2013.01); C07C 2101/02 (2013.01); C07C 2101/04 (2013.01);
Abstract

This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. Specifically gamma-amino alcohol derivatives that inhibit the reuptake of neurotransmitters such as dopamine, serotonin, epinephrine or norepinephrine are provided as therapeutic agents for the treatment of depression or anxiety in a mammalian subject.

Find Patent Forward Citations

Loading…